Therapeutic Effects of Quetiapine and 5-HT1A Receptor Agonism on Hyperactivity in Dopamine-Deficient Mice

Abstract

Some diseases that are associated with dopamine deficiency are accompanied by psychiatric symptoms, including Parkinson’s disease. However, the mechanism by which this occurs has not been clarified. Previous studies found that dopamine-deficient (DD) mice exhibited hyperactivity in a novel environment. This hyperactivity is improved by clozapine and donepezil, which are used to treat psychiatric symptoms associated with dopamine deficiency (PSDD). We considered that DD mice could be used to study PSDD. In the present study, we sought to identify the pharmacological mechanism of PSDD. We conducted locomotor activity tests by administering quetiapine and drugs that have specific actions on serotonin (5-hydroxytryptamine [5-HT]) receptors and muscarinic receptors. Changes in neuronal activity that were induced by drug administration in DD mice were evaluated by examining Fos immunoreactivity. Quetiapine suppressed hyperactivity in DD mice while the 5-HT1A receptor antagonist WAY100635 inhibited this effect. The number of Fos-positive neurons in the median raphe nucleus increased in DD mice that exhibited hyperactivity and was decreased by treatment with quetiapine and 5-HT1A receptor agonists. In conclusion, hyperactivity in DD mice was ameliorated by quetiapine, likely through 5-HT1A receptor activation. These findings suggest that 5-HT1A receptors may play a role in PSDD, and 5-HT1A receptor-targeting drugs may help improve PSDD.

Quetiapine Albumin Nanoparticles as an Efficacious Platform for Brain Deposition and Potentially Improved Antipsychotic Activity

“…As represented in Figure 10 B, rats treated by the QP-NPs significantly crossed the smallest number of squares compared to the rats who received a QP solution either orally or via an IV ( p < 0.05). The observed reduction in the locomotion could have been attributed to the antagonistic effect of quetiapine on the 5-HT2 receptor [ 57 ]. The latter resulted in a spontaneous decrease in the ketamine-induced stimulation effect.…”

Serotonergic and Adrenergic Neuroreceptor Manipulation Ameliorates Core Symptoms of ADHD through Modulating Dopaminergic Receptors in Spontaneously Hypertensive Rats

“…In our study, the expression of 5-HT1A was enhanced after 5-HT1A agonist treatment. In a recent study by Ochiai et al [50], where they tested two 5-HT1A receptor agonists in mitigating hyperactivity in mice, 8-OH-DPAT was able to mitigate the hyperactivity. Wingen et al [41] describe that the 5-HT2A receptor might be involved more in sustained attention compared to divided or selective attention.…”